Physician profile
Leigh Collins
NPI 1538571963
$2,726.48
in general payments reported to CMS, 2019-2025
32 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $145 · 2021: $100 · 2022: $441 · 2023: $493 · 2024: $507 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.45 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $519.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $376.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $321.78 | 2021-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.50 | 2019-2025 | Jardiance |
| Pfizer INC. | $224.89 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $137.31 | 2019 | |
| Glaxosmithkline, LLC. | $133.40 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $66.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $60.12 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.62 | 2019-2023 | Gattex |
| Phathom Pharmaceuticals, INC. | $55.41 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $50.85 | 2024 | Nexletol |
| Qol Medical, LLC | $44.24 | 2023 | Sucraid |
| E.R. Squibb & Sons, L.L.C. | $40.89 | 2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $40.78 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $35.96 | 2023 | Korlym |
| Allergan, INC. | $31.88 | 2019-2020 | |
| Lilly USA, LLC | $31.38 | 2023 | Jardiance |
| Janssen Biotech, INC. | $31.28 | 2022 | |
| Merck Sharp & Dohme LLC | $27.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $25.62 | 2024 | Rexulti |
| Astellas Pharma US INC | $21.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.26 | 2023 | Dupixent |
| Radius Health, INC. | $17.94 | 2020 | |
| Exact Sciences Corporation | $17.88 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $17.56 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.87 | 2025 | Zoryve |
| Nestle Healthcare Nutrition INC. | $13.85 | 2022 | |
| Philips North America LLC | $12.90 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.86 | 2020 | |
| Pacira Therapeutics, INC. | $11.57 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.